SiBone (NASDAQ:SIBN) Stock: Insider Michael Pisetsky Sells 36,241 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 36,241 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $24.80, for a total value of $898,776.80. Following the completion of the transaction, the senior vice president directly owned 40,167 shares in the company, valued at $996,141.60. This trade represents a 47.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

SiBone Stock Down 0.1%

SIBN stock opened at $24.24 on Friday. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92. The company has a quick ratio of 7.55, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. The stock has a market cap of $1.09 billion, a P/E ratio of -78.19 and a beta of 0.64. The business’s 50-day moving average price is $19.81 and its 200-day moving average price is $16.59.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. The company had revenue of $55.70 million during the quarter, compared to analyst estimates of $55.31 million. On average, equities research analysts forecast that SiBone will post -0.34 EPS for the current year.

Key SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

Analysts Set New Price Targets

Several brokerages have recently commented on SIBN. Citigroup restated a “market outperform” rating on shares of SiBone in a research report on Tuesday. Wall Street Zen raised shares of SiBone from a “hold” rating to a “buy” rating in a report on Saturday. TD Cowen upped their target price on shares of SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Finally, Needham & Company LLC decreased their price target on SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, SiBone currently has an average rating of “Moderate Buy” and an average price target of $25.00.

Institutional Investors Weigh In On SiBone

A number of institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co boosted its holdings in shares of SiBone by 26.0% during the 3rd quarter. Diversified Trust Co now owns 34,775 shares of the company’s stock valued at $654,000 after purchasing an additional 7,165 shares during the last quarter. D.A. Davidson & CO. grew its position in shares of SiBone by 2.8% during the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock valued at $711,000 after purchasing an additional 1,038 shares in the last quarter. First Light Asset Management LLC increased its holdings in shares of SiBone by 51.8% in the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of SiBone by 40.3% in the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock worth $1,928,000 after purchasing an additional 33,947 shares during the last quarter. Finally, VELA Investment Management LLC increased its holdings in shares of SiBone by 7.4% in the second quarter. VELA Investment Management LLC now owns 201,094 shares of the company’s stock worth $3,282,000 after purchasing an additional 13,934 shares during the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.